Objective, peer-reviewed reporting on therapeutic peptides, regulatory updates, clinical trial results, and scientific consensus. No hype. No product sales.
Articles tagged FDA.
Retatrutide phase 3 weight-loss results explained, including its triple GIP, GLP-1 and glucagon mechanism and why weight management matters for orthopedic patients.
The FDA peptide reclassification 2026 is a game-changer. Key peptides are moving from Category 2 to Category 1, signaling a new era for therapeutic access. What does this mean for patients and the future of health science?
An updated explanation of the FDA’s April 2026 peptide reclassification, Category 2 removals, upcoming PCAC review, and what the changes may mean for compounding pharmacies and patients.
No articles match that search.